Candesartan Cilexetil/Pioglitazone Hydrochloride

坎地沙坦酯/盐酸吡格列酮

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCandesartan Cilexetil/Pioglitazone Hydrochloride
Drug Alias Name盐酸吡格列酮/坎地沙坦酯TCV-116/pioglitozonePioglitazone Hydrochloride/Candesartan CilexetilTCV-116/ActosCandesartan cilexetil/pioglitazone
ClassificationSmall molecules
Mechanisms of ActionAngiotensin II Receptor Type 1 antagonistsPeroxisome proliferator-activated receptor γ agonists
TargetsAngiotensin II Receptor Type 1Peroxisome proliferator-activated receptor γ
Therapy Area/IndicationsDiabetes Mellitus, Type 2Hypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes Candesartan CilexetilPioglitazone Hydrochloride
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTakeda Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2Hypertension

Other Information

ATC CodeN/A
Related LinksN/A